SB 399885 hydrochloride
目录号 : GC15660
A 5-HT6 receptor antagonist
Cas No.:402713-81-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Twelve male Wistar rats weighing 350 to 400 g at the time of surgery are used. SB-399885 hydrochloride 2.5, 5 and 10 mg/kg or vehicle (1% aqueous solution of Tween 80) (n=6) are administered intraperitoneally in animals adapted to a 12 h dark/12 h light cycle for 4 weeks, starting 2 h after the beginning of the dark period. Each animal receives all 12 treatments. Recordings are begun 15 min later and continued for 6 h. The control solution and SB-399885 hydrochloride are given at least three days apart[1]. |
References: [1]. Monti JM, et al. Effects of the 5-HT6 receptor antagonists SB-399885 and RO-4368554 and of the 5-HT(2A) receptor antagonist EMD 281014 on sleep and wakefulness in the rat during both phases of the light-dark cycle. Behav Brain Res. 2011 Jan 1;216(1):381-8. | |
SB-399885 hydrochloride is a 5-HT6 receptor antagonist.
Compare with the control vehicle SB-399885 hydrochloride 10 mg/kg significantly increases wakefulness (W) (F(3,15)=3.32, P<0.05) while slow wave sleep (SWS), rapid-eye-movement sleep (REMS) and the number of REM periods are reduced (F(3,15)=4.0, P<0.01; F(3,15)=3.14, P<0.05 and F(3,15)=2.62, P<0.05, respectively). Analysis of sleep variables in 2-h blocks shows that SB-399885 hydrochloride 10 mg/kg increases W (F(3,15)=5.48, P<0.01) and reduces SWS (F(3,15)=5.42, P<0.01) and REMS (F(3,15)= 4.05, P<0.01) during the first 2-h period. SB-399885 hydrochloride 5 and 10 mg/kg augment light sleep over the first (F(3,15)=3.46,P<0.01 and F(3,15)= 3.65, P<0.01, respectively) and the second (F(3,15)=3.23, P<0.05 and F(3,15)=3.08, P<0.05, respectively) 2-h recording periods. SB-399885 hydrochloride 10 mg/kg significantly increases REMS latency (F(3,15)=3.60, P<0.01) and reduces the number of REM periods during the first 2-h of recording (F(3,15)=3.88, P<0.01)[1].
References:
[1]. Monti JM, et al. Effects of the 5-HT6 receptor antagonists SB-399885 and RO-4368554 and of the 5-HT(2A) receptor antagonist EMD 281014 on sleep and wakefulness in the rat during both phases of the light-dark cycle. Behav Brain Res. 2011 Jan 1;216(1):381-8.
| Cas No. | 402713-81-9 | SDF | |
| 化学名 | N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-(piperazin-1-yl)benzenesulfonamide hydrochloride | ||
| Canonical SMILES | COC1=C(N2CCNCC2)C=C(S(NC3=CC(Cl)=CC(Cl)=C3OC)(=O)=O)C=C1.Cl | ||
| 分子式 | C18H21Cl2N3O4S.HCl | 分子量 | 482.81 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,PBS (pH 7.2): 10 mg/ml | 储存条件 | Desiccate at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0712 mL | 10.356 mL | 20.7121 mL |
| 5 mM | 0.4142 mL | 2.0712 mL | 4.1424 mL |
| 10 mM | 0.2071 mL | 1.0356 mL | 2.0712 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。